Figures & data
Table 1.
Third adult treatment panel low-density lipoprotein cholesterol treatment targets.
Table 2.
Safety of statins in selected randomized trials, which achieved plasma low-density lipoprotein cholesterol <100 mg/dl.
Holdaas H, Holme I, Schmieder RE, et al. AURORA study group. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol 2011;22(7):1335-41 Narla V, Blaha MJ, Blumenthal RS, Michos ED. The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences. Vasc Health Risk Manag 2009;5:1033-42 Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009;54(5):810-19 Knopp RH, d'Emden M, Smilde JG, Pocock SJ, Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29(7):1478-85 Masson S, Anand I, Favero C, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Valsartan Heart Failure Trial (Val-HeFT) and Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca–Heart Failure (GISSI-HF) Investigators. Circulation 2012;125(2):280-8 Wanner C, Krane V, März W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Deutsche Diabetes-Dialyse-Studie (4D) Study Group. Kidney Blood Press Res 2004;27(4):259-66 Sever PS, Poulter NR, Dahlof B, et al. The anglo-scandinavian cardiac outcomes trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J 2008;29(4):499-508 Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the aggrastat to zocor and pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 trials). Am J Cardiol 2007;100(7):1047-51 LaRosa JC, Grundy SM, Kastelein JJ, et al. Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol 2007;100(5):747-52 Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495-504 Parish S, Offer A, Clarke R, et al. Heart Protection Study Collaborative Group. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012;125(20):2469-78 Holme I, Szarek M, Cater NB, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study. Eur J Cardiovasc Prev Rehabil 2009;16(3):315-20 Armitage J, Bowman L, Wallendszus K, et al. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376(9753):1658-69 Arampatzis CA, Goedhart D, Serruys PW, et al. LIPS Investigators. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention -- a Lescol Intervention Prevention Study (LIPS) substudy. Am Heart J 2005;149(2):329-35